Impact and Risks of Chronic Anemia in Thalassemia Patients

Farrukh Shah

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

PKD: Diagnosis, Treatment and Monitoring for Complications

Stanford Medicine

M. Chien

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

Severe Anemia: Indications for Blood Transfusion, Initial Work Up, a…

APP2APP Virtual Lectures, Inc

D. Thomas

Defining Risk of Progression in CHIP/CCUS: A Pathologists' Perspecti…

16th International Congress on Myeloproliferative Neoplasms

R. Hasserjian

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Current and Emerging Treatment Approaches for Patients With AML or M…

University of Miami Sylvester Comprehensive Cancer Center

S. Venugopal

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Chronic GvHD: Main Complications After ASCT

Steven Pavletic